Redeye provides an update following Q-linea’s Q4 2025 report.
Redeye has updated its estimates and valuation for Sleep Cycle following the Q4 2025 report.
Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-le...
Raute reports Q4 results on Feb 12. Wood Processing has already demonstrated very high margins so th...
Sleep Cycle’s Q4 report was in line with our top-line expectations but revealed a steeper-than-antic...
Redeye provides an initial take following Q-linea’s Q4 2025 report.
While the current valuation profile of Vitrolife requires more than the current stagnant growth prof...
Redeye updates on Invisio ahead of Q4-results (due 12 February) where we expect the company to end t...
Redeye retains its positive view of Addnode following a solid Q4 report.
* Continued soft demand and hourly prices * '26e-'27e EBITA down 3% * Trading at ~5x NTM EV/EBITA, ~...
We lower sales by 4% and cut EBIT by SEK 4-12m in 2026E-28E.
* Mixed Q4 but continued operational leverage * Estimates down on adj.
Redeye comments on ExpreS2ion’s announcement of updated Phase I immunogenicity data for its HER2-tar...
CapMan makes another exit from its Buyout funds as the company just announced exit of PDSVISION from...
Vaisala reports Q4 results on Feb 12. We believe Vaisala’s FY’25 EBITA improved only slightly y/y, w...
Consti reports Q4 results on February 6th, which we expected to be quite in line with previous year ...
* 24% organic sales growth in Q4 (ABGSCe +27%) Adj.
Redeye comments on Addnode’s Q4 report, showing a solid EBITA beating our expectations by 4%.
Vitrolife’s Q4 report came in very close to our projections, reflecting modest underlying growth and...
Redeye initiates coverage of ExpreS2ion Biotech, a clinical-stage Scandinavian biotech company devel...
